ReviewFrontiers in immunology2025
Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking the Anticancer Potential of Patchouli Leaves: Molecular Mechanisms and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sinonasal small-cell neuroendocrine carcinoma (SCNEC) is an uncommon malignant epithelial neuroendocrine tumor in the sinonasal cavity that often presents in isolation and rarely occurs in synchronous fashion with small-cell lung carcinoma (SCLC). Here, we present a case of a 65-year-old man diagnosed with SCNEC concurrently combined with SCLC. He received first-line platinum-doublet chemotherapy combined with durvalumab, followed by radiotherapy to thoracic as well as head and neck regions. The follow-up computed tomography and magnetic resonance imaging showed a complete response according to Response Evaluation Criteria in Solid Tumors criteria until 9 June 2024. This case highlights the need for accurate diagnostic characterization of primary lesions and the need to formalize treatment paradigms using chemotherapy, radiation therapy, immunotherapy with immune checkpoint inhibitors, and targeted prophylactic cranial irradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.